HASSELT, Belgium--(BUSINESS WIRE)--MabCure, Inc. (“MabCure”) (OTCBB: MBCI), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, provides update on recent developments, contracts, and corporate activity that have occurred over the past twelve months.
